Citations

Mayo Clinic

Showing 10 of 108602 citations.

Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma
Pašić, Ivan , Wong, Kit Man , Lee, Jonghun J., Espin‐Garcia, Osvaldo , Brhane, Yonathan , Cheng, Dangxiao , Patel, Devalben, Brown, Catherine , Bucur, Roxana , Reisman, David , Knox, Jennifer J. , Hung, Rayjean J., Liu, Geoffrey , Cleary, Sean P. , Hung, Rayjean J. , Hung, Rayjean J , Liu, Geoffrey , Cleary, Sean P , Chen, Zhuo , Xu, Wei , Knox, Jennifer J

Molecular Carcinogenesis | September 11, 2017 | Volume: 57 | Issue: 1 | Pages: 106-113

10.1002/mc.22736 | PMID 28892201 Get It

Polymorphisms in the promoter of the BRM gene, a critical subunit of the chromatin remodeling SWI/SNF complex, have previously been implicated in risk and prognosis in Caucasian‐predominant lung, head and neck, esophageal, and pancreatic cancers, and in hepatocellular cancers in Asians. We investigated the role of these polymorphisms in hepatocellular carcinoma (HCC) risk and prognosis. HCC cases were recruited in a comprehensive cancer center while the matched controls were recruited from family practice units from the same catchment area. For risk analyses, unconditional logistic regression analyses were performed in HCC patients and matched healthy controls. Overall survival analyses were performed using Cox proportional hazard models, Kaplan‐Meier curves, and log‐rank tests. In 266 HCC cases and 536 controls, no association between either BRM promoter polymorphism (BRM‐741 or BRM‐1321) and risk of HCC was identified (P > 0.10 for all comparisons). There was significant worsening of overall survival as the number of variant alleles increased: BRM‐741 per variant allele adjusted hazards ratio (aHR) 5.77, 95% confidence interval (CI) 2.89‐11.54 and BRM‐1321 per variant allele aHR 4.09, 95%CI 2.22‐7.51. The effects of these two polymorphisms were at least additive, where individuals who were double homozygotes for the variant alleles had a 45‐fold increase in risk of death when compared to those who were double wild‐type for the two polymorphisms. Two BRM promoter polymorphisms were strongly associated with HCC prognosis but were not associated with increased HCC susceptibility. The association was strongest in double homozygotes for the allele variants.
Predictors of Pancreatic Cancer–Associated Weight Loss and Nutritional Interventions
Nemer, Laura, Krishna, Somashekar G. , Shah, Zarine K. , Conwell, Darwin L. , Cruz‐Monserrate, Zobeida , Dillhoff, Mary , Guttridge, Denis C. , Hinton, Alice , Manilchuk, Andrei , Pawlik, Timothy M. , Schmidt, Carl , Talbert, Erin E. , Bekaii‐Saab, Tanios , Hart, Phil A. , Krishna, Somashekar G , Bekaii-Saab, Tanios S , Pawlik, Timothy M

Pancreas | September 11, 2017 | Volume: 46 | Issue: 9 | Pages: 1152-1157

10.1097/mpa.0000000000000898 | PMID 28902785 Get It

Objectives Pancreatic ductal adenocarcinoma (PDAC) is often accompanied by weight loss. We sought to characterize factors associated with weight loss and observed nutritional interventions, as well as define the effect of weight loss on survival. Methods Consecutive subjects diagnosed with PDAC (N = 123) were retrospectively evaluated. Univariate analysis was used to compare subjects with and without substantial (>5%) weight loss. Multivariate logistic regression was performed to identify factors associated with weight loss, and survival analyses were performed using Kaplan-Meier curves and Cox survival models. Results Substantial weight loss at diagnosis was present in 71.5% of subjects and was independently associated with higher baseline body mass index, longer symptom duration, and increased tumor size. Recommendations for nutrition consultation and pancreatic enzyme replacement therapy occurred in 27.6% and 36.9% of subjects, respectively. Weight loss (>5%) was not associated with worse survival on multivariate analysis (hazard ratio, 1.32; 95% confidence interval, 0.76–2.30), unless a higher threshold (>10%) was used (hazard ratio, 1.77; 95% confidence interval, 1.09–2.87). Conclusions Despite the high prevalence of weight loss at PDAC diagnosis, there are low observed rates of nutritional interventions. Weight loss based on current criteria for cancer cachexia is not associated with poor survival in PDAC.
How is the Weather? Forecasting Inpatient Glycemic Control
Saulnier, George E., Castro, Janna C. , Thompson, Bithika , Cook, Curtiss B. , Thompson, Bithika M

Future Science OA | September 11, 2017 | Volume: 3 | Issue: 4 | Pages: No page available

10.4155/fsoa-2017-0066 | PMID 29134125 Get It

Nursing Home Use Across The Spectrum of Cognitive Decline: Merging Mayo Clinic Study of Aging With CMS MDS Assessments
Emerson, Jane A., Long, Kirsten Hall , Ransom, Jeanine E. , Roberts, Rosebud O., Duhig, Amy, Petersen, Ronald C. , Leibson, Cynthia L., Smith, Carin Y. , Hass, Steven

Journal of the American Geriatrics Society | September 11, 2017 | Volume: 65 | Issue: 10 | Pages: 2235-2243

10.1111/jgs.15022 | PMID 28892128 Get It

Background/objectives Objective, complete estimates of nursing home ( NH ) use across the spectrum of cognitive decline are needed to help predict future care needs and inform economic models constructed to assess interventions to reduce care needs. Design Retrospective longitudinal study. Setting Olmsted County, MN . Participants Mayo Clinic Study of Aging participants assessed as cognitively normal ( CN ), mild cognitive impairment ( MCI ), previously unrecognized dementia, or prevalent dementia (age = 70–89 years; N = 3,545). Measurements Participants were followed in Centers for Medicare and Medicaid Services (CMS) Minimum Data Set (MDS) NH records and in Rochester Epidemiology Project provider‐linked medical records for 1‐year after assessment of cognition for days of observation, NH use (yes/no), NH days, NH days/days of observation, and mortality. Results In the year after cognition was assessed, for persons categorized as CN , MCI , previously unrecognized dementia, and prevalent dementia respectively, the percentages who died were 1.0%, 2.6%, 4.2%, 21%; the percentages with any NH use were 3.8%, 8.7%, 19%, 40%; for persons with any NH use, median NH days were 27, 38, 120, 305, and median percentages of NH days/days of observation were 7.8%, 12%, 33%, 100%. The year after assessment, among persons with prevalent dementia and any NH use, >50% were a NH resident all days of observation. Pairwise comparisons revealed that each increase in cognitive impairment category exhibited significantly higher proportions with any NH use. One‐year mortality was especially high for persons with prevalent dementia and any NH use (30% vs 13% for those with no NH use); 58% of all deaths among persons with prevalent dementia occurred while a NH resident. Conclusions Findings suggest reductions in NH use could result from quality alternatives to NH admission, both among persons with MCI and persons with dementia, together with suitable options for end‐of‐life care among persons with prevalent dementia.
Bone Marrow Aspiration for Regenerative Orthopedic Intervention: Technique with Ultrasound Guidance for Needle Placement
Arthurs, Jennifer R. , Shapiro, Shane A.

Regenerative Medicine | September 11, 2017 | Volume: 12 | Issue: 8 | Pages: 917-928

10.2217/rme-2017-0109 | PMID 28891421 Get It

Surgical Treatment of Hepatocellular Carcinoma
Zamora‐Valdés, Daniel , Taner, Timuçin , Nagorney, David M.

Cancer Control | September 11, 2017 | Volume: 24 | Issue: 3 | Pages: 107327481772925

10.1177/1073274817729258 | PMID 28975836 Get It

Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. In select patients, surgical treatment in the form of either resection or transplantation offers a curative option. The aims of this review are to (1) review the current American Association for the Study of Liver Diseases/European Association for the Study of the Liver guidelines on the surgical management of HCC and (2) review the proposed changes to these guidelines and analyze the strength of evidence underlying these proposals. Three authors identified the most relevant publications in the literature on liver resection and transplantation for HCC and analyzed the strength of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) classification. In the United States, the liver allocation system provides priority for liver transplantation to patients with HCC within the Milan criteria. Current evidence suggests that liver transplantation may also be indicated in certain patient groups beyond Milan criteria, such as pediatric patients with large tumor burden or adult patients who are successfully downstaged. Patients with no underlying liver disease may also benefit from liver transplantation if the HCC is unresectable. In patients with no or minimal (compensated) liver disease and solitary HCC ≥2 cm, liver resection is warranted. If liver transplantation is not available or contraindicated, liver resection can be offered to patients with multinodular HCC, provided that the underlying liver disease is not decompensated. Many patients may benefit from surgical strategies adapted to local resources and policies (hepatitis B prevalence, organ availability, etc). Although current low-quality evidence shows better overall survival with aggressive surgical strategies, this approach is limited to select patients. Larger and well-designed prospective studies are needed to better define the benefits and limits of such approach.
C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity
Lee, Youn‐Bok , Baskaran, Pranetha , Gomez-Deza, Jorge, Nishimura, Agnes L. , Smith, Bradley , Troakes, Claire , Adachi, Yoshitsugu, Stepto, Alan, Petrucelli, Leonard , Gallo, Jean‐Marc , Hirth, Frank , Rogelj, Boris , Guthrie, Sarah , Shaw, Christopher E. , Chen, Han-Jou , Troakes, Claire

Human Molecular Genetics | September 11, 2017 | Volume: 26 | Issue: 24 | Pages: 4765-4777

10.1093/hmg/ddx350 | PMID 28973350 Get It

Role of Admission Troponin‐T and Serial Troponin‐T Testing in Predicting Outcomes in Severe Sepsis and Septic Shock
Vallabhajosyula, Saraschandra , Sakhuja, Ankit , Geske, Jeffrey B. , Poterucha, Joseph T., Jaffe, Allan S. , Vallabhajosyula, Saraschandra , Geske, Jeffrey B , Kumar, Mukesh , Kashyap, Rahul , Kashani, Kianoush , Jaffe, Allan S. , Jentzer, Jacob C.

Journal of the American Heart Association | September 9, 2017 | Volume: 6 | Issue: 9 | Pages: No page available

10.1161/jaha.117.005930 | PMID 28889100 Get It

Background Troponin‐T elevation is seen commonly in sepsis and septic shock patients admitted to the intensive care unit. We sought to evaluate the role of admission and serial troponin‐T testing in the prognostication of these patients. Methods and Results This was a retrospective cohort study from 2007 to 2014 on patients admitted to the intensive care units at the Mayo Clinic with severe sepsis and septic shock. Elevated admission troponin‐T and significant delta troponin‐T were defined as ≥0.01 ng/mL and ≥0.03 ng/mL in 3 hours, respectively. The primary outcome was in‐hospital mortality. Secondary outcomes included 1‐year mortality and lengths of stay. During this 8‐year period, 944 patients met the inclusion criteria with 845 (90%) having an admission troponin‐T ≥0.01 ng/mL. Serial troponin‐T values were available in 732 (78%) patients. Elevated admission troponin‐T was associated with older age, higher baseline comorbidity, and severity of illness, whereas significant delta troponin‐T was associated with higher severity of illness. Admission log 10 troponin‐T was associated with unadjusted in‐hospital (odds ratio 1.6; P =0.003) and 1‐year mortality (odds ratio 1.3; P =0.04), but did not correlate with length of stay. Elevated delta troponin‐T and log 10 delta troponin‐T were not significantly associated with any of the primary or secondary outcomes. Admission log 10 troponin‐T remained an independent predictor of in‐hospital mortality (odds ratio 1.4; P =0.04) and 1‐year survival (hazard ratio 1.3; P =0.008). Conclusions In patients with sepsis and septic shock, elevated admission troponin‐T was associated with higher short‐ and long‐term mortality. Routine serial troponin‐T testing did not add incremental prognostic value in these patients.
Characterization of isolated amyloid myopathy
Liewluck, Teerin , Milone, Margherita , Liewluck, T , Milone, M

European Journal of Neurology | September 9, 2017 | Volume: 24 | Issue: 12 | Pages: 1437-1445

10.1111/ene.13448 | PMID 28888072 Get It

Background and purpose Amyloid myopathy frequently occurs in the setting of systemic amyloidosis and less commonly in isolation (isolated amyloid myopathy). Anoctaminopathy‐5 and dysferlinopathy were recently recognized as causes of isolated amyloid myopathy. The present study aimed to characterize the isolated amyloid myopathy and to compare it with amyloid myopathy associated with systemic amyloidosis. Methods We searched the Muscle Laboratory database to identify patients with pathologically confirmed amyloid myopathy seen in neurology clinics between January 1998 and September 2016. Patients with monoclonal gammopathy, peripheral neuropathy, organomegaly or symptoms or pathologic evidence of amyloid deposition outside skeletal muscle were classified as having systemic amyloidosis‐associated myopathy. Results Fifty‐two patients were identified, including 14 with isolated amyloid myopathy (eight anoctaminopathy‐5, two dysferlinopathy and four genetically unknown) and 38 with systemic amyloidosis (32 immunoglobulin light‐chain amyloidosis, four familial amyloid polyneuropathy and two senile systemic amyloidosis). Compared with patients with systemic amyloidosis, patients with isolated amyloid myopathy had a younger age of onset (median, 41.5 vs. 65 years), no dysphagia (0% vs. 26%) or weight loss (0% vs. 26%), but more frequent calf atrophy (57% vs. 0%), small collections of inflammatory cells on muscle biopsy (43% vs. 0%) and asymptomatic hyper CK emia at onset (21% vs. 0%). All patients with isolated amyloid myopathy had creatine kinase (CK) values >2.5 times the upper limit of normal. Conclusions Isolated amyloid myopathy accounts for 27% of patients with amyloid myopathy, mostly due to anoctaminopathy‐5. There are various clinical and laboratory parameters that can help to differentiate isolated amyloid myopathy from systemic amyloidosis.
Tokyo Guidelines 2018: management strategies for gallbladder drainage in patients with acute cholecystitis (with videos)
Mori, Yasuhisa , Itoi, Takao , Baron, Todd H. , Takada, Tadahiro , Strasberg, Steven M. , Pitt, Henry A. , Ukai, Tomohiko , Shikata, Satoru , Noguchi, Yoshinori , Kim, Myung‐Hwan , Asbun, Horacio J. , Endo, Itaru , Yokoe, Masamichi, Miura, Fumihiko, Okamoto, Kohji , Umezawa, Akiko , Iwashita, Yukio , Hibi, Taizo , Wakabayashi, Go , Choi, In‐Seok , Hwang, Tsann‐Long , Chen, Miin‐Fu , Garden, O. James , Singh, Harjit , Liau, Kui‐Hin, Huang, Wayne Shih‐Wei, Gouma, Dirk J., Belli, Giulio, Dervenis, Christos, Santibáñes, Eduardo de , Giménez, Mariano , Windsor, John A. , Lau, Wan Yee , Cherqui, Daniel , Jagannath, P., Supe, Avinash , Liu, Keng‐Hao, Su, Cheng‐Hsi, Deziel, Daniel J., Fan, Sheung Tat , Ker, Chen‐Guo , Jonas, Eduard , Padbury, Robert , Sugioka, Atsushi , Asai, Koji , Higuchi, Ryota , Wada, Keita, Yoshida, Masahiro , Mayumi, Toshihiko , Sumiyama, Yoshinobu, Inui, Kazuo, Yamamoto, Masakazu , Teoh, Anthony Yuen Bun , Suzuki, Kenji S. , Han, Ho-Seong , Yoon, Yoo-Seok , Chen, Xiao‐Ping , Mukai, Shuntaro , Honda, Goro , Hirata, Koichi , Jonas, Eduard

Journal of Hepato-Biliary-Pancreatic Sciences | September 9, 2017 | Volume: 25 | Issue: 1 | Pages: 87-95

10.1002/jhbp.504 | PMID 28888080 Get It

Abstract Since the publication of the Tokyo Guidelines in 2007 and their revision in 2013, appropriate management for acute cholecystitis has been more clearly established. Since the last revision, several manuscripts, especially for alternative endoscopic techniques, have been reported; therefore, additional evaluation and refinement of the 2013 Guidelines is required. We describe a standard drainage method for surgically high‐risk patients with acute cholecystitis and the latest developed endoscopic gallbladder drainage techniques described in the updated Tokyo Guidelines 2018 ( TG 18). Our study confirmed that percutaneous transhepatic gallbladder drainage should be considered the first alternative to surgical intervention in surgically high‐risk patients with acute cholecystitis. Also, endoscopic transpapillary gallbladder drainage or endoscopic ultrasound‐guided gallbladder drainage can be considered in high‐volume institutes by skilled endoscopists. In the endoscopic transpapillary approach, either endoscopic naso‐gallbladder drainage or gallbladder stenting can be considered for gallbladder drainage. We also introduce special techniques and the latest outcomes of endoscopic ultrasound‐guided gallbladder drainage studies. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.